MODULAR NEXT GENERATION

CELL THERAPY

NEW & INNOVATING THERAPIES

CYTEA|BIO IS DEVELOPING THERAPIES BY COMBINING GENETICALLY UNMODIFIED EFFECTOR CELLS AND TARGETING LIGANDS.

ITS PLATFORM ENABLES PRACTICALLY LIMITLESS COMBINATIONS OF EFFECTOR MECHANISMS AND TARGETS, BUILDING NEW AND INNOVATIVE THERAPIES WITHOUT NEED FOR DRUG DISCOVERY.

4+

(POTENTIAL PRODUCT CANDIDATES)

(THE COMPANY)

OUR COMPANY

CYTEA|BIO IS A FRENCH BIOTECHNOLOGY STARTUP BASED IN MONTPELLIER DEDICATED TO THE DEVELOPMENT OF CELL THERAPY PRODUCTS.

3+

(MILLIONS RAISED)

6+

(YEARS OF ACADEMIC RESEARCH BEHIND THE PLATFORM)

CYTEA|BIO developed a patented cell therapy platform (pin™ platform). The platform enables to pin Fc- engineered mAbs and Fc-based ligands at the surface of any effector cell.
The platform enables therapeutic use of unmodified autologous and allogeneic effector cells, combined with single or multiple ligands, providing appropriate sensing, targeting, activation and therapeutic effect.

(CONCEPT)

OUR TECHNOLOGY

PLATFORM

EFFECTOR CELLS AND TARGETING LIGANDS

Unmodified human effector cells armed with engineered antibodies or engineered Fc ligands, selected to target disease markers

PIPELINE

TREATING VARIOUS PATHOLOGIES

ROBUST PRE-CLINICAL POC ACHIEVED WITH ANTI-CD20 ARMED NK CELLS. LEAD TUMOR PROGRAM IN GLIOBLASTOMA MULTIFORME (GBM).

(LEADERSHIP)

OUR TEAMS

EXPERIENCED

MULTIDISCIPLINARY SKILLS

(01)

INTERNATIONAL

INTERNATIONAL COLLABORATIONS

(02)

TOP EXECUTIVES

BEST PROFILES

(03)

(SUPPORT)

OUR PARTNERS